Nitromed axes BiDil sales reps

Share this article:

Nitromed announced it plans to lay off a majority of its newly hired BiDil sales force by roughly 70 to 90 employees.

Nitromed doubled its sales force from 30 to 60 specialist reps during the second half of 2007 to boost BiDil. “However, with only modest improvement in sales, management concluded that it cannot sustain BiDil marketing efforts alone,” wrote Friedman, Billings, Ramsey & Co. analyst Robert Uhl in a recent note to investors. Nitromed now expects to file the NDA for BiDil XR with the FDA in 2010. Nitromed has hired an investment bank to explore strategic options, which could lead to sale of the company, Uhl wrote. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.